# Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer

> **NCT01664182** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 41 (actual)

## Conditions studied

- Advanced Renal Cell Carcinoma
- Advanced Sarcomatoid Renal Cell Carcinoma
- Stage III Renal Cell Cancer AJCC v7
- Stage IV Renal Cell Cancer AJCC v7

## Interventions

- **BIOLOGICAL:** Bevacizumab
- **DRUG:** Pazopanib Hydrochloride
- **DRUG:** Sorafenib Tosylate
- **DRUG:** Sunitinib Malate
- **BIOLOGICAL:** Trebananib

## Key facts

- **NCT ID:** NCT01664182
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08-01
- **Primary completion:** 2020-12-07
- **Final completion:** 2020-12-07
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2022-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01664182

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01664182, "Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01664182. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*